“Chemo Brain” Can Persist for 2 Decades

TON - April 2012, Vol 5, No 3 published on April 27, 2012 in In the News

The term “chemo brain” was coined to describe mild cognitive problems in cancer patients attributed to chemotherapy. Although minor chemotherapy-induced memory and cognitive impairments have been described previously, a case-cohort study suggests that these effects can persist more than 20 years posttherapy. 

The authors state that chemo brain effects are subtle compared with women who never had chemotherapy, but it’s possible that these effects place people at greater risk for cognitive decline associated with aging. 

A partial explanation for chemo brain may be that chemotherapy penetrates the blood-brain barrier, killing healthy brain cells, or that chemotherapy affects the immune system or is proinflammatory. 

The study, published online in February in the Journal of Clinical Oncology (Koppelmans V, Breteler MM, Boogerd W, et al) included 196 breast cancer survivors treated with adjuvant CMF (cyclophosphamide, methotrexate, and fluorouracil) who were tested with a series of cognitive and memory tests. Ages were from 50 to 80 years, the mean number of chemotherapy cycles was 6, and the mean interval since chemotherapy was 21 years. Scores on speed processing, word, memory, and general cognitive functioning tests were compared with scores of a population-based sample of 1509 women who did not undergo cancer treatment and were participants in a larger long-term study. 

Women treated with chemotherapy scored significantly lower on tests of immediate and delayed verbal memory, processing speed, executive function, and psychomotor speed than the reference group and similarly on the other 10 tests included in the study. The intergroup differences were small. On word learning tests, women who had chemotherapy had an average score of 24.3 of 45 compared with a score of 25.5 in the control group.

Senior author Sanne Schagen, MD, Netherlands Cancer Institute, Amsterdam, the Netherlands, said that these differences might or might not be apparent, depending on the specific tasks involved in people’s daily lives. Someone in a demanding job might notice these changes in cognition, but someone who is not working and has a more relaxed lifestyle may not.

One limitation of this study is that CMF is an older chemotherapy regimen no longer considered a standard of care. However, Dr Schagen noted that more modern drugs would probably cause the same effects.

Other limitations include the inability to prove cause and effect between chemotherapy and cognitive changes, which may be an effect of breast cancer itself. Also, baseline mental function was not assessed prior to chemotherapy. 

The study does not imply that women with breast cancer should not undergo chemotherapy. Rather, the implication is that patients and physicians should be aware of the potential cognitive effects of chemotherapy and seek help if these problems interfere with daily function. 

The effects documented in this study do not appear to be serious cognitive impairment or even mild cognitive impairment, but patients are scoring slightly lower on tests of memory and thinking, explained neuropsychologist Barbara Collins, PhD, Ottawa Hospital, Ontario, Canada, who was not involved in this study. 

Related Items
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
Yvette Florio Lane
Web Exclusives published on June 12, 2019 in FDA Approvals, News & Updates, In the News
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation
Web Exclusives published on May 7, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Web Exclusives published on April 23, 2019 in FDA Approvals, News & Updates, In the News, Renal-Cell Carcinoma
April 16, 2019 – FDA Approvals, News & Updates
Web Exclusives published on April 16, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Web Exclusives published on March 22, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Web Exclusives published on March 15, 2019 in FDA Approvals, News & Updates, In the News
March 08, 2019 – FDA Approvals, News & Updates
Web Exclusives published on March 8, 2019 in FDA Approvals, News & Updates, In the News
Last modified: May 21, 2015